Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This study is ongoing, but not recruiting participants.
Study NCT00004248 Information provided by National Cancer Institute (NCI)
First Received: January 28, 2000 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Liver Cancer
Additional conditions recognized in this trial
Carcinoma, Hepatocellular
Liver Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
aldesleukin
doxorubicin hydrochloride
Additional drug interventions recognized in this trial
Doxorubicin
Interleukin-2
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
